The FDA updated the label of a cancer drug to include that certain patients with early chronic myeloid leukemia (CML) may be able to stop taking the treatment after they’ve responded well to it over time. The new update indicates that patients with CML who have been taking Tasigna (nilotinib) for 3 years or more, and whose leukemia has responded to treatment based on FDA criteria, may be able to discontinue use of the cancer drug. In the past, patients with CML remained on the drug indefinitely. While musculoskeletal symptoms such as body aches, bone pain and pain in extremities are among the most common side effects, Tasigna’s labeling contains a black-box warning alerting doctors and patients about the risk of abnormal heart rhythm (QT prolongation) and sudden death. Posted December 22, 2017. Via FDA.
Alanna McCatty is founder and CEO of McCatty Scholars, an organization that devises and implements financial literacy programs for students to combat the nationwide issue of the loss of educational opportunity due to the ramifications of burdensome student debt. At MedShadow, she reports on new findings and research on the side effects of prescription drugs. She is a graduate of Pace University.
Did you find this article helpful?
No votes so far! Be the first to rate this post.